
|Videos|July 7, 2016
The Ideal Patient Population for the Use of Nivolumab in Treatment of NSCLC
Author(s)Hossein Borghaei, DO
Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the ideal patient population that can potentially benefit from the use of nivolumab in the treatment of non-small cell lung cancer.



















